PatientsVille.com Logo


Oscal Medical Research Studies

Up-to-date List of Oscal Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Oscal Medical Research Studies

Rank Status Study
1 Recruiting A Study of Changes in Bone Mineral Density as a Function of Consuming Two Different Forms of Calcium Carbonate
Condition: Osteopenia, Osteoporosis
Interventions: Dietary Supplement: Micronized Calcium Carbonate;   Dietary Supplement: Non-Micronized Calcium Carbonate;   Dietary Supplement: Vitamin D3
Outcome Measures: Change from baseline in Bone Mineral Density as a measurement by Dual Energy X-ray Absorptiometry;   Blood Chemistry Panel;   Systolic and Diastolic blood pressure;   Resting heart rate;   Self-reported quality of life;   Number of participants with adverse effects
2 Unknown  Amorphous Calcium Carbonate (Acc) Versus Crystalline Calcium Carbonate (Ccc) Using Stable Calcium Isotopes In Postmenopausal Women
Condition: Postmenopause
Interventions: Other: CCC;   Other: ACC
Outcome Measure: Mean change in fractional absorption of calcium from amorphous calcium carbonate (ACC) Vs. crystalline calcium carbonate (CCC).
3 Recruiting Safety and Effectiveness of an Intracranial Aneurysm Embolization System for Treating Large or Giant Wide Neck Aneurysms
Condition: Brain Aneurysm
Intervention: Device: Surpass Flow Diverter
Outcome Measures: Primary Effectiveness;   Primary Safety;   Secondary Safety
4 Recruiting Active Surveillance Post-Approval Atudy of the Stelkast Surpass Acetabular System
Condition: Survivorship and Long-term Safety and Effectiveness of the Stelkast Surpass Acetabular System
Intervention: Device: Stelkast Surpass Acetabular System implant
Outcome Measure:
5 Recruiting The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23
Condition: Other Nonspecific Abnormal Serum Enzyme Levels
Interventions: Drug: Lanthanum carbonate;   Drug: Calcium Carbonate
Outcome Measure: serum level of fibroblast growth factor
6 Recruiting Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study
Conditions: Hemodialysis;   Hyperphosphatemia
Interventions: Drug: Lanthanum Carbonate;   Drug: Calcium Carbonate
Outcome Measures: Cardiovascular event free survival time.;   Overall survival;   Secondary hyperparathyroidism free survival;   Hip fracture free survival;   Quality of life questionnaire (KDQOL-SF, v1.3);   Bone mineral density (DEXA)
7 Not yet recruiting A Study Comparing the Effect of Amorphous Calcium Carbonate (ACC) on Healing Time of Distal Radius Fractures
Condition: Distal Radius Fractures
Intervention: Dietary Supplement: Amorphous calcium carbonate
Outcome Measures: Change from baseline in radiographic fracture healing;   Change from baseline in improvement of function;   Change from baseline in reduction of symptoms and signs related to distal radius fractures;   Assessment of calcium side effects;   Change from baseline in fracture gap and callus calcification
8 Recruiting A Comparison of Lanthanum Carbonate and Calcium Carbonate in Children
Condition: Hyperphosphataemia in Chronic Kidney Disease
Interventions: Drug: Lanthanum carbonate;   Drug: Calcium carbonate
Outcome Measures: Percentage of subjects achieving age-specific Kidney Disease Outcomes Quality Initiative (KDOQI) targets for serum phosphorus;   Change from baseline in serum phosphorus at up to 8 weeks;   Change from Baseline in Calcium Levels at up to 8 weeks;   Change from baseline in Calcium-Phosphorous Product at up to 8 Weeks;   Maximum Plasma Concentration (Cmax) of Lanthanum Carbonate;   Area Under the Plasma Concentration-Time Curve from time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Lanthanum Carbonate;   Change from baseline in serum phosphorus at up to 10 Months;   Change from Baseline in Calcium Levels at up to 10 Months;   Change from baseline in Calcium-Phosphorous Product at up to 10 Months;   Change from baseline in Bone Alkaline Phosphatase (ALP) at Up to 10 Months;   Change from Baseline in Tartrate-Resistant Acid Phosphatase (TRAP) at Up to 10 Months;   Change from Baseline Osteocalcin levels at Up to 10;   Change from Baseline in Fibroblast Growth factor 23 (FGF-23) Levels at Up to 10 Months;   Change from Baseline in Parathyroid Hormone (PTH) Levels at Up to 10 Months;   Change from Baseline in Sclerostin Levels at Up to 10 Months;   Change from Baseline in Fetuin-A Levels at Up to 10 Months;   Change from Baseline in Height at up to 10 Months;   Change from Baseline in Weight at Up to 10 Months
9 Not yet recruiting A Study Comparing Amorphous Calcium Carbonate (ACC) Versus Crystalline Calcium CCS) in Hypoparathyroidism Patients
Condition: Hypoparathyroidism
Interventions: Dietary Supplement: amorphous calcium carbonate;   Dietary Supplement: crystalline calcium supplements
Outcome Measures: Calcium (albumin-corrected) serum level - composite value based on multiple measurements;   Urine calcium level - 24h urine collection;   Phosphorous serum level - composite value based on multiple measurements;   Assessment of symptoms and signs related with hypocalcemia - composite value based on multiple measurements;   Urine creatinine level - 24h urine collection;   Urine phosphorus level - 24h urine collection
10 Not yet recruiting Two phosphAte taRGets in End-stage Renal Disease Trial (TARGET)
Condition: End-stage Renal Disease
Interventions: Drug: Calcium carbonate ( Intensive phosphate control);   Drug: Calcium carbonate (Liberalized phosphate control)
Outcome Measures: Serum phosphate concentration;   Number of patients who successfully achieved target serum P at week 26 based on the arm to which they were randomized;   Treatment compliance as defined by taking the study medication at least 80% of the time;   Number of serious adverse events;   Number of hospitalizations for vascular reasons that are unrelated to dialysis access;   Proportion of patients with a vascular death or non-fatal vascular event;   Proportion of patients developing serum calcium > 2.60 mmol/L;   Number of fractures;   Number of patients developing calcific uremic arteriolopathy (ie, calciphylaxis);   Change in quality-of-life
11 Recruiting Effects of Vitamin D and Calcium Supplementation on Inflammatory Biomarkers and Adypocytokines in Diabetic Patients
Condition: Nutritional and Metabolic Disease
Interventions: Dietary Supplement: vitamin D3 supplement;   Dietary Supplement: calcium supplement;   Dietary Supplement: vitamin D3 and calcium supplement;   Dietary Supplement: placebo
Outcome Measures: change in inflammatory biomarkers from baseline at 8 weeks;   change in adipocytokines from baseline at 8 weeks;   change in weight (Kg) from baseline at 8 weeks;   change in lipid profile from baseline at 8 weeks;   change in serum Glucose from baseline at 8 weeks;   change in height (Cms) from baseline at 8 weeks;   change in hip circumference (Cms) from baseline at 8 weeks;   change in waist circumference (Cms) from baseline at 8 weeks;   change in serum Insulin from baseline at 8 weeks;   change in HbA1C from baseline at 8 weeks;   change in blood pressure from baseline at 8 weeks
12 Not yet recruiting Calcium Supplements Strategy for Kidney Stones Prevention in Crohn's Patients
Conditions: Kidney Calculi;   Crohn's Disease
Intervention: Dietary Supplement: Calcium Carbonate
Outcome Measures: Molar ratio of urinary calcium:oxalate in relation to the supersaturation product of calcium oxalate;   Optimal level of Ca supplementation for prevention of stones in Crohn's patients
13 Unknown  ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Outcome Measure:
14 Recruiting Magnetic Resonance Biomarkers in Neonatal Encephalopathy
Condition: Neonatal Encephalopathy
Outcome Measure: Prognostic accuracy of [NAA]
15 Recruiting Study of Parental Ratings of Quality of Life and Body Composition in 5-19 Year Olds While Participating in the Good NEWS 4 Kids Program
Conditions: Quality of Life;   Body Mass Index
Interventions: Dietary Supplement: MannaBears;   Dietary Supplement: AlgaeCal Calcium;   Dietary Supplement: Calcium carbonate;   Dietary Supplement: Vitamin D3
Outcome Measures: Change from baseline in parental ratings of participating child's quality of life;   Changes in body composition as a measurement of Dual Energy Absorptiometry;   Changes in hip to waist ratios;   Changes in blood pressure;   Changes in gender and age adjusted BMI
16 Recruiting Nutrition and Body Composition in Acute Lymphoblastic Leukemia
Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma;   Vitamin D Deficiency
Intervention: Dietary Supplement: Vitamin D and Calcium Citrate
Outcome Measures: Repletion of serum Vitamin D Status;   To describe the relationship between Vitamin D, adipose tissue, and bone density in patients with ALL undergoing induction and post-remission therapy and in early survivors;   To measure the effect of Vitamin D supplementation on changes in bone density;   To compare the prevalence of obesity and Vitamin D deficiency in adolescents with newly diagnosed ALL and in their siblings
17 Recruiting Bone Metabolism After Laparoscopic Gastric Bypass Surgery (BABS)
Conditions: Evaluation of Expected Bone Loss After Bariatric Surgery;   Possible Prevention of Bone Loss After Surgery by Calcium and Vitamin D Supplementation
Intervention: Drug: Calciferol, calcium carbonate
Outcome Measures: Evaluation of bone mineral density changes in obese patients after laparoscopic bariatric surgery;   Evaluation of changes of serum bone turnover markers in obese patients after laparoscopic bariatric surgery
18 Recruiting Efficacy of Vitamin D and Calcium Supplementation on the Prevention of Recurrences in BPPV
Condition: Benign Paroxysmal Positional Vertigo
Intervention: Drug: 400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate
Outcome Measures: Recurrence rate of benign paroxysmal positional vertigo;   Changes in serum 25-hydroxy vitamin D level;   Falling frequency;   Fracture frequency;   Quality of life
19 Recruiting Phase 2 Reduction of Dietary Mycotoxin Exposure by ACCS100"
Condition: Dietary Carcinogenesis
Interventions: Drug: ACCS100;   Drug: Placebo
Outcome Measures: Reduction of dietary mycotoxin (Aflatoxin-AFB1 and Fumonisin-FB1) exposure in participants in Bexar County, Texas;   Compare side-effects and adverse events between ACCS100 and placebo in the participant population
20 Recruiting Vitamin D, Insulin Resistance, and Cardiovascular Disease
Conditions: Vitamin D Deficiency;   Insulin Resistance;   Type 2 Diabetes Mellitus;   Cardiovascular Disease;   Hypertension
Interventions: Drug: Vitamin D3;   Drug: Placebo
Outcome Measures: Hypertension;   Brachial artery response to hyperemia;   Systemic inflammatory markers and macrophage inflammatory response to modified-lipoproteins;   Serum and urinary calcium measurements

These studies may lead to new treatments and are adding insight into Oscal etiology and treatment.

A major focus of Oscal research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Oscal